| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Previous Article | Next Article ![]()
Eukaryotic Cell, October 2004, p. 1164-1168, Vol. 3, No. 5
1535-9778/04/$08.00+0 DOI: 10.1128/EC.3.5.1164-1168.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Institut für Mikrobiologie, Heinrich-Heine-Universität, Düsseldorf, Germany
Received 14 May 2004/ Accepted 30 June 2004
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
In fungi, O glycosylation at serine or threonine residues occurs in the ER (reviewed in references 5 and 21). Mannosyltransferase (Pmt) proteins catalyze O mannosylation of proteins traversing the secretory pore. In Saccharomyces cerevisiae, the PMT family encodes seven isoforms, and the human fungal pathogen Candida albicans has five isoforms (Pmt1, -2, -4, -5, and -6), which modify specific target proteins (7, 14, 17, 18, 23, 24). The close coupling of secretion and O glycosylation in fungi suggested that the latter process, like N glycosylation in higher eukaryotes, is functionally related to folding and/or the stability of secretory glycoproteins. It was shown that in S. cerevisiae a fraction of a model protein, mutant alpha-factor precursor, was partially protected from proteasomal degradation by Pmt2p-mediated O mannosylation (8). In addition, O mannosylation of Axl2p by Pmt4p (18) and of surface sensors Wsc1p, Wsc2p, and Mid2p by Pmt2p/Pmt4p (14, 17) prevents a specific proteolytic cleavage. In C. albicans, Als1p, chitinase, and Kre9p are targets for Pmt1p (23, 24; S. K.-H. Prill, B. Klinkert, C. Timpel, and J. F. Ernst, unpublished data), but protective O mannosylation has not been reported.
Sec20p is an essential type II membrane protein of the ER that functions as part of a complex containing the tSNARE Ufe1p involved in retrograde vesicle traffic in S. cerevisiae and C. albicans (4, 13, 22, 25, 26). In sec20 mutants, retrograde and consequently anterograde traffic of secretory vesicles is blocked; in addition, Golgi glycosylation is defective (19). We show here that C. albicans Sec20p is an O-glycosylated protein, which in its nonglycosylated form, in mutants lacking Pmt1p or Pmt4p isoforms, or in Sec20p variants lacking potential O-glycosylation sites is rapidly degraded. Thus, Sec20p is the first example of an essential component of the eukaryotic secretory apparatus and of an ER membrane protein that is effectively protected from proteolytic degradation in the ER by specific Pmt-mediated O glycosylation.
| MATERIALS AND METHODS |
|---|
|
|
|---|
ura3::imm434
ura3::imm434) (6) and its mutated derivatives, including the pmt1 mutant CAP1-3121 (pmt1
::hisG pmt1
::hisG) (21), the pmt4 mutant CAP4-2164 (Prill et al., unpublished), the pmt6 mutant CAP2-1341 (pmt4
::hisG pmt4
::hisG) (22), and the mnt1 mutant NGY24 (mnt4
::hisG mnt4
::hisG) (1). Strains were grown in YPD medium or on supplemented SD minimal medium at 30°C (20). Transformation of C. albicans strains was carried out by the spheroplast method (20). The expression plasmids pYW7, encoding a PCK1p-SEC20 fusion, and pYW69, encoding a PCK1p-SEC20-myc fusion, have been described (24). The PCK1 promoter in transformants was repressed in S4D medium (SD medium with 4% glucose) and induced in SCAA medium (0.67% yeast nitrogen base, 2% Casamino Acids) or SLac medium (0.67% yeast nitrogen base, 2% sodium lactate) (12) supplemented by a mix of amino acids (20) but lacking methionine and cysteine.
SEC20 mutagenesis.
The SEC20 expression vector pYW69 was mutated by specific oligonucleotides, using the QuikChange site-directed mutagenesis kit (Stratagene). Plasmids pYW96 (S268A), pYW98 (S272A, S274A), pYW94 (S279A, S280A), pYW92 (T285A, T286A), pYW97 (T294A, T296A), pYW95 (T300A, S302A), pYW93 (T321A, T322A, S323A, S324A), pYW91 (N201A), pYW
K245 (K245A), pYW
K253 (K253A), pYW
K268 (K268A), and pYW
K294 (K294A) were constructed.
Preparation of crude extracts and immunoblottings. Twenty milliliters of cells were grown in SCAA medium to an optical density at 600 nm of 1 to 4 and harvested by centrifugation (5 min; 2,150 x g). The cell pellet was washed twice with water and resuspended in 500 µl of RE buffer (50 mM HEPES-KOH; 150 mM NaCl; 5 mM EDTA; 1% Triton X-100; 1 µg of protease inhibitors antipain, pepstatin A, and leupeptin [Sigma]/ml; pH 7.5). An equal volume of glass beads (diameter, 0.25 to 0.5 mm) was added, and the cells were shaken on a Vibrax VX 2E (Janke and Kunkel) at maximum speed at 4°C. The cell debris and beads were pelleted by centrifugation (3 min; 2,150 x g) and discarded, while the supernatant was considered the crude extract. Protein concentrations were determined by the Bradford assay using a commercial kit (Bio-Rad).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting were carried out as described previously (26). An anti-c-myc antibody (9E10; Babco) diluted 1:500 was used as the primary antibody, while polyclonal goat anti-mouse antibody coupled to peroxidase (Jackson Research Laboratory, Inc.), diluted 1:60,000, was used as the secondary antibody. Staining was done with Super-SignalULTRA chemoluminescent substrate (Pierce). Anti-ubiquitin antibody (Babco) was used at a dilution of 1:200.
Binding to ConA.
According to a previous protocol (22), crude extracts were prepared from 10 ml of cells as described above, but using concanavalin A (ConA) buffer (1.6% Triton X-100, 0.1% SDS, 0.5 M NaCl, 20 mM sodium phosphate buffer, pH 7.6) during cell breakage. Crude extract (120 µl; 2.5 µg of protein/µl) was split into two 60-µl portions that were treated differently. One portion was incubated with 100 µl of ConA-Sepharose and 900 µl of ConA buffer for 4 h at 4°C and then centrifuged (45 s at 16,060 x g). The resulting supernatant containing mostly unglycosylated Sec20p was designated S1, while the ConA-Sepharose pellet was resuspended again in 1 ml of ConA buffer and treated for 45 min at room temperature before being centrifuged as before. The resulting ConA-Sepharose pellet was resuspended in Laemmli buffer and labeled fraction P1, while the corresponding supernatant was designated S2. The second portion of the crude extract was treated similarly, except that 10% methyl
-D-mannopyranoside was present in the second incubation and after centrifugation, pellet P3 and a supernatant fraction, S3, were obtained.
Pulse-chase experiments. To maximally induce the PCK1p-SEC20-myc fusion, cells were grown twice in SLac medium before being harvested by centrifugation. Twenty units of cells at an optical density at 600 nm of 1 in the exponential growth phase were pelleted and resuspended in 2.5 ml of SLac medium. Following preincubation at 30°C for 20 min, 100 µCi of [35S]methionine (TRAN35S-LABEL; ICN) was added, and the cells were incubated for 15, 20, or 45 min (pulse). Thereafter, 1/50 volume of chase solution (0.3% cysteine, 0.4% methionine) was added, and incubation was continued for various times (chase). At each time point, an aliquot of 500 µl was removed, and the cells were pelleted by brief centrifugation and resuspended in 1 ml of ice-cold 10 mM NaN3. After another centrifugation step, the cell pellet was resuspended in 110 µl of lysis buffer (0.3 M sorbitol, 50 mM HEPES, 10 mM NaN3, pH 7.5), transferred to a microcentrifuge tube containing 250 mg of glass beads (diameter, 0.25 to 0.5 mm), and shaken at maximum speed on a Vibrax VX 2E for 7 min. One hundred microliters of 2x Laemmli sample buffer was added, and proteins were denatured at 95°C for 10 min.
For immunoprecipitation, 800 µl of IP dilution buffer (1.25% Triton X-100, 6 mM EDTA, 60 mM Tris-HCl, pH 7.6) was added to 200 µl of the denatured proteins, and insoluble cell material was pelleted by centrifugation at 16,060 x g for 2 min. Five microliters of anti-c-myc antibody (9E10; Babco) was added, and the solution was incubated overnight at 4°C; 50 µl of a 20% solution of protein A-Sepharose in IP buffer was added, and incubation was continued for 4 h at 4°C. Following centrifugation (16,060 x g; 20 s), a pellet was obtained, which was washed three times with washing buffer (1% Triton X-100, 0.2% SDS, 150 mM NaCl, 5 mM EDTA, 50 mM Tris-HCl, pH 7.6), and then 50 µl of IP buffer, 50 µl of 2x Laemmli buffer, and 100 mM dithiothreitol was added, and the proteins were denatured at 95°C for 10 min. Following SDS-PAGE (11.5% acrylamide), the gel was bathed first in fixing solution (20% methanol, 7% acetic acid) for 30 min and then for 30 min in Amplify Fluorgraphic Reagent (Amersham). Proteins were detected by autoradiography.
| RESULTS |
|---|
|
|
|---|
-D-mannopyranoside, both forms were released (S3). In control experiments with transformants synthesizing untagged Sec20p (encoded by plasmid pYW7), no significant signals were detected by immunoblotting (Fig. 1).
|
Sec20p is not detectable in pmt1 and pmt4 mutants. To examine Sec20p in mutants lacking known components of O glycosylation in C. albicans, we transformed pYW69 into a pmt1 mutant (23), a pmt4 mutant (Prill et al., unpublished), a pmt6 mutant (24), and an mnt1 mutant lacking the transferase extending monomannosylated proteins (1).
Following SDS-PAGE, the three electrophoretic forms of Sec20-Myc were observed in the wild-type strain and the pmt6 mutant but not in pmt1 and pmt4 mutants (Fig. 2). Minor bands detected in pmt mutants appear to be due to proteins in the extract that cross-react with the anti-Myc antibody, because they were also seen repeatedly in extracts of a control strain producing untagged Sec20p (data not shown and Fig. 3). The mnt1 strain contained the 50-kDa major form but none or little of the 38.6- and 110-kDa forms. We conclude from these results (i) that to obtain wild-type levels of Sec20p, specific Pmt isoforms, Pmt1p and Pmt4p, are required; (ii) that the major 50-kDa form of Sec20p is monomannosylated at multiple O-glycosylation sites; and (iii) that the 110-kDa form either contains extended O-glycosyl chains or consists of a stable dimer of the 50-kDa form.
|
|
We first established the parameters of Sec20p labeling in the PMT1 wild-type genetic background of strain CAI4. After pulse-labeling, the 38.6-kDa unglycosylated and 50-kDa O-glycosylated forms could be immunoprecipitated, while the 110-kDa form found in immunoblots was absent (Fig. 3A), suggesting that it is synthesized only after extended times (>100 min). Labeling of a control strain, producing untagged Sec20p, revealed only a doublet of nonspecific proteins. By pulse-labeling for 15 min and subsequent chase, we detected a clear precursor-product relationship between the 38.6-kDa form that was synthesized first and the 50-kDa form, which arose during the chase. From autoradiographies, we deduce a half-time of
15 min for the disappearance of the 38.6-kDa form and the appearance of the 50-kDa form; once produced, the 50-kDa form is stable for extended times (>100 min).
In the pmt1 genetic background, Sec20-Myc was initially synthesized as in the control strain (Fig. 3B). However, the 50-kDa form did not occur in the pmt1 mutant, and only minor bands, also found in the untagged Sec20p control, were detected in the 50-kDa range. Instead, the 38.6-kDa form disappeared with a half-time of
15 min, indicating that it was degraded. This result showed that the low level of Sec20p production in the pmt1 mutant was not caused by lack of SEC20 expression or defective Sec20p biosynthesis but was due to an inability to produce the stable O-glycosylated 50-kDa form.
In additional experiments, we also tested whether a 200 µM concentration of the proteasomal inhibitor lactacystin would lead to stabilization of Sec20-Myc in a pmt1 strain during a pulse-chase experiment. However, no significant stabilization was achieved (data not shown), and the possibility that lactacystin is unable to enter C. albicans, like S. cerevisiae, cannot be excluded (11). Because ubiquitination is a prerequisite for proteasomal degradation, we also tested whether Sec20-myc could be coimmunoprecipitated with ubiquitin (detected with a monoclonal anti-yeast ubiquitin antibody) in a wild-type or a pmt1 strain (data not shown). No ubiquitination of Sec20p was observed in this experiment, which is consistent with (but does not positively prove) the notion that Sec20p is degraded independently of the proteasome (3).
Biosynthesis of Sec20p in mutants lacking potential glycosylation and ubiquitination sites.
Sec20p is a type II membrane protein that in C. albicans directs a portion of
100 C-terminal residues oriented toward the lumen of the ER. Because it is known that Pmt proteins O mannosylate proteins at the lumenal side of the ER, we examined Sec20-Myc variants mutated in the lumenal domain to delete potential O glycosylation sites. A schematic view of the Sec20p lumenal domain, which is rich in Ser and Thr residues, and the locations of serine- or threonine-to-alanine replacements of the variants are shown in Fig. 4, top.
|
Because during ERAD, ubiquitin may get attached to Sec20p, we also tested the biosynthesis of variants, in which lysine residues within the ER lumenal domain, some situated adjacent to potential serine or threonine mannosylation sites, were changed to alanine (Fig. 4). However, such variants were not stabilized in pmt1 mutants (data not shown), suggesting that there is more than a single site for ubiquitination in the lumenal domain, that ubiquitination occurs elsewhere, or that Sec20p is degraded via a ubiquitination- and proteasome-independent pathway.
| DISCUSSION |
|---|
|
|
|---|
-agglutinin, and Kre1/9p are targets of Pmt1p and Pmt2p; Kex2p, Gas1p, Fus1p, and Axl2p are targets of Pmt4p (reviewed in reference 21); while Mid2p and Wsc1p are targets of Pmt2p and Pmt4p (14, 17). Some of these proteins, namely, Axl2p, Wsc1p, Wsc2p, and Mid2p, are prevented by Pmt2/4p-mediated O glycosylation from undergoing specific proteolytic cleavage (14, 17, 18). The stabilization of Sec20p in C. albicans described here represents the first case of the stabilization of an ER membrane protein by Pmt-mediated O mannosylation, which may be a paradigm for eukaryotic cells, including mammalian cells, which contain homologues of Pmt proteins that are active in O mannosylation (15, 27). It will be of interest to determine if among species, homologous proteins are subject to the same principle of protective O mannosylation or if this phenomenon is protein and species specific.
The molecular mechanism by which Pmt1/4p-mediated O mannosylation protects Sec20p from degradation is not known. In contrast to the known cases of protective O mannosylation (14, 17, 18), Sec20p appears to be completely degraded immediately after its synthesis in a pmt1 mutant (no cleavage products were detected); furthermore, Sec20p is not transiently but permanently associated with the ER, performing an essential function in retrograde vesicle traffic. It is possible that a specific lectin in the ER lumen recognizes monomannosylated proteins to positively retain them in the ER. In a negative model, mannosylation could also prevent recognition by a specific component of the ERAD or by an ER-resident degradation machinery (3). Such mechanisms could be especially important for ER-resident soluble or membrane proteins containing lumenal domains permanently or transiently in an open, noncompact conformation, which would otherwise be constantly and nonproductively removed from the ER by proteolysis. For fungi, protection by O mannosylation may be especially relevant, because protein translocation across the Sec61p translocon is closely coupled to O modification. It has in fact been shown that a mutated version of pre-pro-
-factor in S. cerevisiae is O glycosylated by Pmt2p within the ER and that in a pmt2 mutant its halftime is shortened from 12 to 10 min (8). Although this result supports our general conclusion about stabilization by Pmt-mediated mannosylation, we note important differences in that (i) unlike Sec20p, pre-pro-
-factor is not normally retained in the ER but secreted into the medium after processing; (ii) the rate of stabilization of Sec20p by O mannosylation is significantly greater than in the case of mutant pre-pro-
-factor; (iii) Pmt1p/Pmt4p instead of Pmt2p are involved in the stabilization of Sec20p; and (iv) we did not obtain evidence for an ERAD pathway of degradation, which involves retrograde export across the Sec61 pore and ubiquitination.
Some combinations of mutations in at least three PMT genes prevent the growth of S. cerevisiae (7), while in C. albicans, even a pmt single mutant (pmt2) and a pmt double mutant (pmt1 pmt4) are not viable (Prill et al., unpublished). On the other hand, Sec20p performs an essential function in the secretory pathway (25), suggesting that lack of Sec20p O mannosylation may be one reason why the pmt1 pmt4 double mutant is nonviable. In support of this notion, we found that moderate lowering of SEC20 expression generated a similar phenotype of antifungal supersensitivity (25) compared to pmt1 and pmt4 single mutants (23; Prill et al., unpublished). We assume that in both single mutants, residual mannosylation of Sec20p still occurs, allowing the presence of residual Sec20p in the ER and thereby allowing survival; on the other hand, the lack of both Pmt1p and Pmt4p would lower Sec20p levels below a threshold level not compatible with growth. Concepts for future strategies to combat fungal infections may include antifungals acting on Pmt proteins but could also focus on specific and essential Pmt targets, including Sec20p, for which no close homologue exists in human cells.
| ACKNOWLEDGMENTS |
|---|
This study was supported by the Deutsche Forschungsgemeinschaft and by EU grant QLK2-CT-2001-02377 (Combating MDR in Pathogens).
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Appl. Environ. Microbiol. | Infect. Immun. | J. Bacteriol. |
|---|---|---|
| Mol. Cell Biol. | Microbiol. Mol. Biol. Rev. | ALL ASM JOURNALS |